Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet

Angiotensin-converting enzyme inhibitors have proven to be of clinical benefit in congestive heart failure. Whether they also provide benefit to patients with coronary artery disease in the absence of congestive heart failure via an antiatherosclerotic mechanism is a question the QUinapril Ischemic Event Trial quantitative coronary angiography (QCA) study attempted to answer: 1,750 patients with normal left ventricular function who were undergoing coronary angiography and angioplasty were randomized to 20 mg/day of quinapril versus placebo and followed far 3 years for cardiac end points. A randomly selected subgroup of the total cohort underwent follow-vp angiography, The primary QCA end point was the categorical designation of progression versus nonprogression, defined either by QCA or by a cardiac event in patients selected for the QCA trial who had no usable follow-up x-ray film. Secondary end points in patients with 2 angiograms were: new stenosis development, change in minimum lumen diameter index, and change in percent diameter stenosis index. There were 119 progressors among 243 placebo-treated patients (49%) and 111 progressors among 234 quinapril-treated patients (47%) (p = NS), There were 44 patients with new stenosis developement in the placebo group (19%) and 50 (22%) in the quinapril group (p = NS). Change in minimum lumen diameter index was -0.21 +/- 0.03 mm in the placebo group and -0.18 +/- 0.03 mm in the quinapril group (p = NS), Finally, change in percent diameter stenosis index was +5.1 +/- 1.0 in the placebo group and +3.5 +/- 1.0 in the quinapril group (p = NS), potential confounders of this trial are presented and discussed. (C)1999 by Excerpta Medica, Inc.